Core Viewpoint - The article discusses the key focus areas for the national medical insurance system in China for 2026, emphasizing the goal of making childbirth essentially free nationwide and enhancing the overall management and efficiency of medical insurance funds [1][4]. Group 1: Key Focus Areas for 2026 - The national medical insurance system will focus on consolidating universal coverage and improving the basic medical insurance system [1]. - There will be support for the development of commercial health insurance to establish a multi-tiered medical security system [1]. - Strengthening the management of medical insurance funds to ensure their safety is a priority [1]. Group 2: Childbirth Cost Reduction - The initiative aims for childbirth to be essentially free across the country by 2026, with specific measures to include flexible employment workers and migrant workers in maternity insurance coverage [4]. - Seven provinces, including Jilin, Jiangsu, and Shandong, have already achieved the goal of making childbirth free [4]. - The plan includes enhancing prenatal care coverage and ensuring direct payment of maternity benefits to insured individuals [4]. Group 3: Long-term Care Insurance Development - The long-term care insurance system currently covers approximately 300 million insured individuals and has benefited over 3.3 million disabled individuals [5]. - The focus will be on optimizing long-term care services and encouraging commercial insurance institutions to develop related products [5]. Group 4: Fund Management and Efficiency - The article highlights the importance of the proper use of medical insurance funds, which are crucial for public health [8]. - Measures have been taken to combat fraud, with approximately 120 billion yuan recovered over five years [8]. - The implementation of a new payment system and the promotion of real-time settlement of medical insurance funds are planned for 2026 [10]. Group 5: Drug Procurement and Innovation - The national centralized drug procurement has become a regular practice, with the latest round including 55 drugs aimed at stabilizing clinical use and ensuring quality [12]. - The introduction of a commercial insurance drug directory aims to cover innovative drugs that exceed basic insurance coverage [13]. - The focus on digitalization and artificial intelligence in medical insurance governance is expected to enhance policy implementation and industry vitality [14][15].

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for the sector in the next 6-12 months [9][63]. Core Insights - The medical services sector has shown resilience, with a recent performance boost attributed to the seasonal increase in flu cases, despite ongoing cost control pressures from medical insurance [9][63]. - The report highlights the significance of the recent government initiative to promote provincial-level medical insurance coordination, which is expected to enhance the efficiency of fund utilization and improve the overall healthcare system [5][6][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 31.62, with a Price-to-Book (PB) ratio of 3.18, indicating a slight increase from the previous week [4][29]. Summary by Sections Industry Performance - The pharmaceutical and biological sector experienced a decline of 2.67% this week, ranking 17th among 31 primary industries [2][11]. - The medical services sub-sector reported a slight increase of 1.42%, closing at 6237.83 points [22][23]. Company Performance - Top-performing companies in the medical services sector include ST Zhongzhu (+16.3%), Baihua Pharmaceutical (+11.6%), and Lanwei Medical (+10.6%) [3][27]. - Underperforming companies include Aier Eye Hospital (-1.6%) and WuXi AppTec (-0.7%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.40 from the previous week, while the PB ratio has risen by 0.04 [4][29]. - The maximum and minimum PE ratios over the past year were 41.13 and 28.46, respectively, indicating a relatively stable valuation range [4][29]. Government Policy Impact - The recent government meeting emphasized the importance of provincial-level medical insurance coordination, which aims to balance fund distribution across regions and enhance the overall healthcare system [5][6][61]. - The report identifies structural opportunities for the pharmaceutical industry, particularly in innovative drugs, medical devices, and healthcare information technology, as a result of the new insurance policies [6][62]. Investment Recommendations - The report suggests focusing on high-growth areas such as pharmaceutical outsourcing services and companies with improving profit margins, including WuXi AppTec and Aier Eye Hospital [9][63].